Busting the Breast Cancer with AstraZeneca’s Gefitinib

Table 2

Salient characteristics of breast cancer cell lines in terms of EGFR expression.

Breast cancer cell lines	EGFR	EGFR2	EGFR3	EGFR4	Gefitinib sensitivity
MCF-7 [115]	Low levels [117, 118]	Low levels [117]	Low levels [119]	Naturally expressing [119]	Resistant
SK-BR-3	High abundance [120]	Overexpression [121], amplified [120]	Higher abundance [116]	Naturally expressing [44]	Sensitive [122]
HCC1954	High abundance [116]	Amplified [116]	NA	Not detected [116]	Sensitive [118]
T47D [32]	Low levels [117]	Low levels [117]	High expression	High expression
MCF7/ADR [123]	Overexpression	Overexpression	NA	NA	Resistant
MDA-MB-231 [123]	Overexpression	Low levels	NA	NA	Resistant

EGFR: epidermal growth factor receptor 1; EGFR2: epidermal growth factor receptor 2; EGFR3: epidermal growth factor receptor 3; EGFR4: epidermal growth factor receptor 4; NA: not available.